Literature DB >> 7284239

Anaemia in patients with solid tumours and the role of erythrocyte deformability.

C E Mercke.   

Abstract

The deformability of erythrocytes, which is a factor of utmost importance both for capillary perfusion and for determining erythrocyte life span, has been studied in patients with solid tumours and in healthy subjects. Deformability was significantly decreased in all patients, especially those with anaemia. In this latter group of patients, carboxyhaemoglobin saturation of blood (COHb), reflecting erythrocyte haemoglobin breakdown, was also significantly increased, and this increase was closely correlated with the degree of impaired deformability of the erythrocytes. In the group of patients without anaemia, where erythrocyte deformability was also impaired, no such correlation was found. In 4 patients with Hodgkin's disease and fever as part of B symptoms, erythrocyte deformability decreased during fever and returned to normal when fever subsided. In 2 of these patients the administration of a prostaglandin-synthesis inhibitor (indomethacin) evoked a deformability, which was even better than during periods without fever. Since fever in Hodgkin patients with B symptoms has been attributed to the production of prostaglandins, these results may suggest a relationship between prostaglandin production and erythrocyte deformability in patients with malignant tumours. The close correlation between the degree of decrease in erythrocyte deformability and COHb levels in the patients with anaemia might indicate a role for prostaglandins in the production of anaemia of malignancy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7284239      PMCID: PMC2010761          DOI: 10.1038/bjc.1981.201

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Herediatary spherocytosis. A review.

Authors:  R I Weed
Journal:  Arch Intern Med       Date:  1975-10

2.  The role of the spleen in the hemolytic anemia of cancer patients.

Authors:  J E ULTMANN
Journal:  Cancer Res       Date:  1958-09       Impact factor: 12.701

3.  Erythrophagocytosis in cancer-bearing and lymphoma-bearing mice.

Authors:  R V PONDER; E PONDER
Journal:  Nature       Date:  1958-05-31       Impact factor: 49.962

4.  Erythrocyte filterability and heme catabolism during the menstrual cycle.

Authors:  C Mercke; B Lundh
Journal:  Ann Intern Med       Date:  1976-09       Impact factor: 25.391

5.  Red cells in sickle cell crisis: observations on the pathophysiology of crisis.

Authors:  E E Rieber; G Veliz; S Pollack
Journal:  Blood       Date:  1977-06       Impact factor: 22.113

6.  Reticulo-endothelial activity in humans with cancer.

Authors:  C J Magarey; M Baum
Journal:  Br J Surg       Date:  1970-10       Impact factor: 6.939

7.  Production of prostaglandin E2 by bladder tumor cells in tissue culture and a possible mechanism of lymphocyte inhibition.

Authors:  M J Droller; J A Lindgren; H E Claessen; P Perlmann
Journal:  Cell Immunol       Date:  1979-10       Impact factor: 4.868

8.  Human spleen heme oxygenase and microsomal electron transport system component activity in normals and in patients with hemolytic anemia, idiopathic thrombocytopenic purpura, and lymphoproliferative disorders.

Authors:  B A Schacter; B Yoda; L G Israels
Journal:  J Lab Clin Med       Date:  1979-05

9.  [Perioperative behavior of prostaglandin E2 (PGE2) and 13,14-dihydro-15-keto-PGF2 alpha (DHK-PGF2 alpha) in the serum in bronchial cancer].

Authors:  L Fiedler; G Schlegel; D Kaiser; H P Zahradnik
Journal:  Onkologie       Date:  1979-06

10.  Prostaglandin-like material extracted from squamous carcinomas of the head and neck.

Authors:  A Bennett; R L Carter; I F Stamford; N S Tanner
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

View more
  1 in total

1.  Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.

Authors:  Yunus Alapan; Ceonne Kim; Anima Adhikari; Kayla E Gray; Evren Gurkan-Cavusoglu; Jane A Little; Umut A Gurkan
Journal:  Transl Res       Date:  2016-03-19       Impact factor: 7.012

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.